Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is focused on developing new and more effective therapies to treat cancer. CombiPlex®, the company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the desired ratio in patients to improve clinical outcomes. Celator’s pipeline includes two clinical stage products: CPX-351 for the treatment of acute myeloid leukemia, and CPX-1 for the treatment of colorectal cancer; as well as several preclinical stage product candidates. For more information, visit the company’s website at www.celatorpharma.com